Enterprise Europe Network

Injectable material for the regeneration of articular cartilage

Country of origin:
Country: 
SPAIN
Opportunity:
External Id: 
TOES20190517001
Published
17/05/2019
Last update
28/05/2019
Expiration date
28/05/2020

Keywords

Partner keyword: 
Organic Substances
Pharmaceutics
Pharmaceutical Products / Drugs
Physiotherapy, Orthopaedic Technology
Medical Biomaterials
Cellular and Molecular Biology
Therapeutic services
Orthopaedics
Other chemicals and materials (not elsewhere classified)
Manufacture of basic pharmaceutical products
Other research and experimental development on natural sciences and engineering
EXPRESS YOUR INTEREST

Summary

Summary: 
A Spanish biomedical research networking center has developed a new strategy for the regeneration of articular cartilage based on an injectable material, looking to establish license, research cooperation or technical cooperation agreements.

Description

Description: 

This research networking center gathers some of the main Spanish research groups in biomedicine, located in more than 100 institutions like universities, hospitals, and technological centers distributed around the country.

This new strategy for the regeneration of articular cartilage is based on an injectable material whose implant in the site of a cartilage defect combined with a subchondral bone stimulation technique.

In the regeneration of the articular cartilage, various subchondral bone stimulation techniques are used. These surgical techniques are based on injuring the bone below the site of cartilage damage inducing bleeding that opens a path for the migration of pluripotent, mesenchymal cells with chondrogenic capacity, able to produce new cartilaginous tissue. However, very often the tissue formed does not have the structure or properties of the articular cartilage (hyaline cartilage) but rather it looks more like fibrocartilage, softer, which is not functional in the joint and degenerates with time. One of the reasons why the cells that arrive at the defect site are not able to generate the correct tissue is that the biomechanical environment they find is not adequate. Different implants have been developed that aim to protect the cells and transfer to the cells the dynamic compression loads to which the joint is subjected in a similar way as in healthy tissue, but their efficiency is still not fully demonstrated.

The new material consists of a mixture of synthetic microspheres, SMs (biodegradable polymer), and autologous microspheres, AMs (produced from the patient's own tissue). A bleeding at the defect site is produced by microfracture, nanofracture or drilling of the subchondral bone. The mixture of the two types of microspheres is injected and soaked in the blood being embedded in the blood clot. Next, the defect is covered with a synthetic membrane that sticks to the clot, covering the defect. The surgical procedure can be performed by arthroscopy. Within three months, in a rabbit knee model, the organism has displaced the biomaterial and tissue with the histological aspect of the native one and a fully functional articular surface has replaced the defect.
The Spanish research center is looking for industrial partners, either from the Biotech or Pharma sectors, in order to achieve
license, research cooperation or technical cooperation agreements.

Advantages & innovations

Cooperation plus value: 
This innovative system creates a biomechanical environment in the place of the cartilage defect that is favorable for the chondrogenesis. Pluripotent cells easily invade the place of regeneration. No extracorporeal manipulation of cells is needed. Release of growth factors from the autologous microspheres can be performed.

Stage of development

Cooperation stage dev stage: 
Under development/lab tested

Partner sought

Cooperation area: 
Patent ready for licensing-out. The research center is seeking industrial partners, either Biotech or Pharma, to: - enter into preclinical R&D collaboration (in vivo drug testing) via research cooperation agreements. - Further development until clinical proof-of-concept via license or technical cooperation agreements.

Type and size

Cooperation task: 
SME 11-50,University,R&D Institution,SME <10,251-500,SME 51-250,>500